Chronic Myeloid Leukemia, Version 2.2021

被引：189

作者：

Deininger, Michael W. ^{[1
]}

Shah, Neil P. ^{[2
]}

Altman, Jessica K. ^{[3
]}

Berman, Ellin ^{[4
]}

Bhatia, Ravi ^{[5
]}

Bhatnagar, Bhavana ^{[6
,7
]}

DeAngelo, Daniel J. ^{[8
]}

Gotlib, Jason ^{[9
]}

Hobbs, Gabriela ^{[10
]}

Maness, Lori ^{[11
]}

Mead, Monica ^{[12
]}

Metheny, Leland ^{[13
,14
]}

Mohan, Sanjay ^{[15
]}

Moore, Joseph O. ^{[16
]}

Naqvi, Kiran ^{[17
]}

Oehler, Vivian ^{[18
]}

Pallera, Arnel M. ^{[19
]}

Patnaik, Mrinal ^{[20
]}

Pratz, Keith ^{[21
]}

Pusic, Iskra ^{[22
,23
]}

Rose, Michal G. ^{[24
]}

Smith, B. Douglas ^{[25
]}

Snyder, David S. ^{[26
]}

Sweet, Kendra L. ^{[27
]}

Talpaz, Moshe ^{[28
]}

Thompson, James ^{[29
]}

Yang, David T. ^{[30
]}

Gregory, Kristina M. ^{[31
]}

Sundar, Hema ^{[31
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[6] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH 43210 USA

[7] Solove Res Inst, Columbus, OH USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[9] Stanford Canc Inst, Stanford, CA USA

[10] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[11] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[12] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[13] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[14] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] Duke Canc Inst, Durham, NC USA

[17] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA

[18] Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA

[19] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[20] Mayo Clin, Canc Ctr, Rochester, MN USA

[21] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[22] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[23] Washington Univ, Sch Med, St Louis, MO USA

[24] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[25] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[26] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[27] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[28] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[29] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[30] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[31] Natl Comprehens Canc Network, Plymouth Meeting, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2020年 / 18卷 / 10期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE-KINASE INHIBITORS; CHRONIC-PHASE CML; CLONAL CHROMOSOMAL-ABNORMALITIES; IN-SITU HYBRIDIZATION; PHILADELPHIA-NEGATIVE CELLS; PATIENTS RECEIVING IMATINIB; STANDARD-DOSE IMATINIB; SUBCUTANEOUS OMACETAXINE MEPESUCCINATE; PULMONARY ARTERIAL-HYPERTENSION;

D O I：

10.6004/jnccn.2020.0047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 (t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

引用

页码：1385 / 1415

页数：31

共 273 条

[31] Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory [J].

Bouchet, Stephane ;

Titier, Karine ;

Moore, Nicholas ;

Lassalle, Regis ;

Ambrosino, Basmah ;

Poulette, Sylvie ;

Schuld, Peter ;

Belanger, Coralie ;

Mahon, Francois-Xavier ;

Molimard, Mathieu .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 (06) :690-697

[32] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia [J].

Branford, S. ;

Cross, N. C. P. ;

Hochhaus, A. ;

Radich, J. ;

Saglio, G. ;

Kaeda, J. ;

Goldman, J. ;

Hughes, T. .

LEUKEMIA, 2006, 20 (11) :1925-1930

[33] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[34] Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations [J].

Branford, S ;

Rudzki, Z ;

Parkinson, I ;

Grigg, A ;

Taylor, K ;

Seymour, JF ;

Durrant, S ;

Browett, P ;

Schwarer, AP ;

Arthur, C ;

Catalano, J ;

Leahy, MF ;

Filshie, R ;

Bradstock, K ;

Herrmann, R ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2004, 104 (09) :2926-2932

[35] Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials [J].

Branford, Susan ;

Fletcher, Linda ;

Cross, Nicholas C. P. ;

Mueller, Martin C. ;

Hochhaus, Andreas ;

Kim, Dong-Wook ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Pane, Fabrizio ;

Kamel-Reid, Suzanne ;

Wang, Y. Lynn ;

Press, Richard D. ;

Lynch, Kevin ;

Rudzki, Zbigniew ;

Goldman, John M. ;

Hughes, Timothy .

BLOOD, 2008, 112 (08) :3330-3338

[36] Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia [J].

Branford, Susan ;

Kim, Dennis Dong Hwan ;

Apperley, Jane F. ;

Eide, Christopher A. ;

Mustjoki, Satu ;

Ong, S. Tiong ;

Nteliopoulos, Georgios ;

Ernst, Thomas ;

Chuah, Charles ;

Gambacorti-Passerini, Carlo ;

Mauro, Michael J. ;

Druker, Brian J. ;

Kim, Dong-Wook ;

Mahon, Francois-Xavier ;

Cortes, Jorge ;

Radich, Jerry P. ;

Hochhaus, Andreas ;

Hughes, Timothy P. .

LEUKEMIA, 2019, 33 (08) :1835-1850

[37] Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease [J].

Branford, Susan ;

Wang, Paul ;

Yeung, David T. ;

Thomson, Daniel ;

Purins, Adrian ;

Wadham, Carol ;

Shahrin, Nur Hezrin ;

Marum, Justine E. ;

Nataren, Nathalie ;

Parker, Wendy T. ;

Geoghegan, Joel ;

Feng, Jinghua ;

Shanmuganathan, Naranie ;

Mueller, Martin C. ;

Dietz, Christian ;

Stangl, Doris ;

Donaldson, Zoe ;

Altamura, Haley ;

Georgievski, Jasmina ;

Braley, Jodi ;

Brown, Anna ;

Hahn, Christopher ;

Walker, Ieuan ;

Kim, Soo-Hyun ;

Choi, Soo-Young ;

Park, Sa-Hee ;

Kim, Dong-Wook ;

White, Deborah L. ;

Yong, Agnes S. M. ;

Ross, David M. ;

Scott, Hamish S. ;

Schreiber, Andreas W. ;

Hughes, Timothy P. .

BLOOD, 2018, 132 (09) :948-961

[38] Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline [J].

Branford, Susan ;

Yeung, David T. ;

Parker, Wendy T. ;

Roberts, Nicola D. ;

Purins, Leanne ;

Braley, Jodi A. ;

Altamura, Haley K. ;

Yeoman, Alexandra L. ;

Georgievski, Jasmina ;

Jamison, Bronte A. ;

Phillis, Stuart ;

Donaldson, Zoe ;

Leong, Mary ;

Fletcher, Linda ;

Seymour, John F. ;

Grigg, Andrew P. ;

Ross, David M. ;

Hughes, Timothy P. .

BLOOD, 2014, 124 (04) :511-518

[39] Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases [J].

Breccia, Massimo ;

Cannella, Laura ;

Montefusco, Enrico ;

Frustaci, Annamaria ;

Pacilli, Matteo ;

Alimena, Giuliana .

LEUKEMIA RESEARCH, 2008, 32 (03) :519-520

[40] Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority [J].

Bumm, T ;

Müller, C ;

Al-Ali, HK ;

Krohn, K ;

Shepherd, P ;

Schmidt, E ;

Leiblein, S ;

Franke, C ;

Hennig, E ;

Friedrich, T ;

Krahl, R ;

Niederwieser, D ;

Deininger, MWN .

BLOOD, 2003, 101 (05) :1941-1949

← 1 2 3 4 5 6 7 8 9 10 →